Safety and Tolerability of Indacaterol Maleate/Mometasone Furoate Delivered Via the Twisthaler® Device After 14 Days Treatment in Patients With Mild to Moderate Asthma

• Status: Completed
• Trial end date: 2008-04-01

Summary

This study will investigate the safety and tolerability of indacaterol maleate/mometasone furoate via the Twisthaler device after 14 days treatment in patients with mild to moderate asthma.

• Phase: Phase 2

Details

• Lead Sponsor: Novartis
• Collaborator: Merck Sharp & Dohme Corp.
• Treatments: Maleic acid; Mometasone Furoate